TWI787230B - 抗ＴＧＦ-β抗體及其用途 - Google Patents

抗ＴＧＦ-β抗體及其用途 Download PDF

Info

Publication number
TWI787230B
TWI787230B TW107101789A TW107101789A TWI787230B TW I787230 B TWI787230 B TW I787230B TW 107101789 A TW107101789 A TW 107101789A TW 107101789 A TW107101789 A TW 107101789A TW I787230 B TWI787230 B TW I787230B
Authority
TW
Taiwan
Prior art keywords
cancer
tgf
antibody
seq
cells
Prior art date
Application number
TW107101789A
Other languages
English (en)
Chinese (zh)
Other versions
TW201833135A (zh
Inventor
蓋瑞 夏皮羅
凱文 布勞爾
派翠克 芬恩
理查 格雷戈里
拉歐 柯都里
鋒 劉
納塔利婭 瑪爾科娃
帕明德 米高
傑克 波拉德
華偉 邱
約阿希姆 泰哈柏
克里斯多福 溫特
翠琤 俞
Original Assignee
法商賽諾菲公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商賽諾菲公司 filed Critical 法商賽諾菲公司
Publication of TW201833135A publication Critical patent/TW201833135A/zh
Application granted granted Critical
Publication of TWI787230B publication Critical patent/TWI787230B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107101789A 2017-01-20 2018-01-18 抗ＴＧＦ-β抗體及其用途 TWI787230B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762448800P 2017-01-20 2017-01-20
US62/448,800 2017-01-20
??17305061.8 2017-01-20
EP17305061 2017-01-20
EP17305061.8 2017-01-20

Publications (2)

Publication Number Publication Date
TW201833135A TW201833135A (zh) 2018-09-16
TWI787230B true TWI787230B (zh) 2022-12-21

Family

ID=61656071

Family Applications (3)

Application Number Title Priority Date Filing Date
TW107101789A TWI787230B (zh) 2017-01-20 2018-01-18 抗ＴＧＦ-β抗體及其用途
TW113140547A TW202506185A (zh) 2017-01-20 2018-01-18 抗TGF-β抗體及其用途
TW111145565A TWI856437B (zh) 2017-01-20 2018-01-18 抗TGF-β抗體及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW113140547A TW202506185A (zh) 2017-01-20 2018-01-18 抗TGF-β抗體及其用途
TW111145565A TWI856437B (zh) 2017-01-20 2018-01-18 抗TGF-β抗體及其用途

Country Status (21)

Country Link
US (4) US10766955B2 (enExample)
JP (3) JP7213186B2 (enExample)
CN (2) CN117417939A (enExample)
AU (2) AU2018209391B2 (enExample)
BR (1) BR112019014787A2 (enExample)
CA (1) CA3050845A1 (enExample)
CL (1) CL2019002011A1 (enExample)
CO (1) CO2019008946A2 (enExample)
CR (1) CR20190375A (enExample)
DO (1) DOP2019000191A (enExample)
EC (1) ECSP19059553A (enExample)
IL (3) IL268112B2 (enExample)
MA (1) MA47311A (enExample)
MX (2) MX2019008551A (enExample)
MY (1) MY200751A (enExample)
PE (1) PE20200734A1 (enExample)
PH (1) PH12019501635A1 (enExample)
SG (1) SG11201906660TA (enExample)
TW (3) TWI787230B (enExample)
UY (1) UY37575A (enExample)
ZA (1) ZA201904494B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
MX2021000304A (es) * 2018-07-10 2021-04-12 Sanofi Sa Terapias combinadas dirigidas a cd38 y tgf-beta.
EP3844181B1 (en) 2018-08-30 2025-11-12 ImmunityBio, Inc. Multi-chain chimeric polypeptides and uses thereof
KR20210069639A (ko) 2018-08-30 2021-06-11 에이치씨더블유 바이올로직스, 인크. 단일-사슬 키메라 폴리펩타이드 및 이의 용도
KR20210117271A (ko) * 2018-12-21 2021-09-28 노쓰웨스턴유니버시티 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
EP3739588A1 (en) * 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
CN114269903B (zh) 2019-06-21 2025-11-25 免疫生物公司 多链嵌合多肽和其用途
IL295077A (en) 2020-02-11 2022-09-01 Hcw Biologics Inc Methods of treating age-related and inflammatory diseases
US12398189B2 (en) 2020-02-11 2025-08-26 HCW Biologics, Inc. Methods of activating regulatory T cells
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
EP4355363A1 (en) 2021-06-18 2024-04-24 Genzyme Corporation Anti-tgf-beta antibody formulations and their use
CN117957013A (zh) 2021-08-11 2024-04-30 Hcw生物科技公司 多链嵌合多肽及其在肝脏疾病治疗中的用途
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
IL312489A (en) * 2021-11-01 2024-07-01 Genzyme Corp Treatment of defective bone formation
JP2025512378A (ja) 2022-04-13 2025-04-17 イミュニティバイオ，インコーポレーテッド 概日時計遺伝子障害の処置における使用のための多重鎖キメラポリペプチド
CA3248139A1 (en) 2022-04-13 2023-10-19 Immunitybio Inc CHIMERIC MULTI-CHAIN POLYPEPTIDE INTENDED FOR USE IN THE TREATMENT OF A NEURO-INFLAMMATORY DISORDER
CN115508565B (zh) * 2022-10-20 2024-11-15 成都医学院第一附属医院 Cilp1作为肾纤维化生物标志物的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961003A (zh) * 2004-03-31 2007-05-09 健泰科生物技术公司 人源化抗TGF－β抗体
WO2014153435A1 (en) * 2013-03-20 2014-09-25 Genzyme Corporation Methods for treating osteogenesis imperfecta
TW201540726A (zh) * 2014-01-23 2015-11-01 再生元醫藥公司 針對ｐｄ－１的人類抗體

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
AU6278298A (en) 1997-02-14 1998-09-08 Salk Institute For Biological Studies, The Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
ZA988461B (en) 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20020063763A1 (en) 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
NZ571243A (en) 2002-12-31 2010-04-30 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
MX2007009545A (es) 2005-02-08 2008-03-11 Genzyme Corp Anticuerpos para tgfbeta.
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
EP2666787B1 (en) 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US20110189206A1 (en) 2008-01-03 2011-08-04 Barbas Iii Carlos F Antibody Targeting Through a Modular Recognition Domain
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
US8361469B2 (en) 2008-12-22 2013-01-29 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
EP2421559B1 (en) 2009-04-24 2016-07-20 Vanderbilt University Anti-tgf-beta induction of bone growth
ES2638521T5 (es) 2010-03-05 2021-03-02 Univ Johns Hopkins Composiciones y métodos para anticuerpos y proteínas de fusión inmunomoduladores dirigidos contra dianas
MX354359B (es) 2011-03-29 2018-02-28 Roche Glycart Ag Variantes de fragmento cristalizable (fc) de los anticuerpos.
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
CN116333113A (zh) 2011-06-03 2023-06-27 佐马技术有限公司 对TGF-β具有特异性的抗体
CN103732626A (zh) 2011-06-13 2014-04-16 艾比吉诺米克斯合作公司 抗psgl-1抗体及其用途
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN104379603B (zh) 2012-05-31 2017-11-07 先天制药公司 Tlr3结合剂
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014062978A1 (en) * 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
SI2981822T1 (sl) 2013-05-06 2021-08-31 Scholar Rock, Inc. Sestavki in postopki za modulacijo rastnega dejavnika
EP3044234B9 (en) 2013-09-13 2020-08-26 BeiGene Switzerland GmbH Anti-pd1 antibodies and their use as therapeutics and diagnostics
BR112016013896A2 (pt) 2013-12-17 2017-10-10 Genentech Inc métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170216401A1 (en) 2014-03-17 2017-08-03 Piotr Jachimczak Combination for use in a method of treating cancer
US20180265874A1 (en) 2014-10-10 2018-09-20 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
KR102513870B1 (ko) * 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
WO2016161410A2 (en) * 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
RS60753B1 (sr) 2015-04-17 2020-10-30 Bristol Myers Squibb Co Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
ES3028883T3 (en) 2015-08-31 2025-06-20 Nat Res Council Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
US20190216943A1 (en) 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961003A (zh) * 2004-03-31 2007-05-09 健泰科生物技术公司 人源化抗TGF－β抗体
WO2014153435A1 (en) * 2013-03-20 2014-09-25 Genzyme Corporation Methods for treating osteogenesis imperfecta
TW201540726A (zh) * 2014-01-23 2015-11-01 再生元醫藥公司 針對ｐｄ－１的人類抗體

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 John-Paul Silva et al. The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation. J Biol Chem. 290(9). Epub 2015 Jan 7. 5462-5469. *

Also Published As

Publication number Publication date
IL268112A (en) 2019-09-26
PH12019501635A1 (en) 2019-11-04
TW202506185A (zh) 2025-02-16
ZA201904494B (en) 2020-12-23
IL268112B2 (en) 2025-09-01
PE20200734A1 (es) 2020-07-23
AU2024264593A1 (en) 2024-12-05
IL311866A (en) 2024-06-01
US20220195026A1 (en) 2022-06-23
BR112019014787A2 (pt) 2020-02-27
US20250026821A1 (en) 2025-01-23
JP2020514310A (ja) 2020-05-21
MX2023002588A (es) 2023-03-22
US11242384B2 (en) 2022-02-08
US10766955B2 (en) 2020-09-08
MA47311A (fr) 2019-11-27
CN117417939A (zh) 2024-01-19
MY200751A (en) 2024-01-13
US12049496B2 (en) 2024-07-30
IL268112B1 (en) 2025-05-01
JP7411832B2 (ja) 2024-01-11
IL311866B1 (en) 2025-11-01
CN110520441A (zh) 2019-11-29
CN117417939A8 (zh) 2024-07-12
ECSP19059553A (es) 2019-08-30
US20200399358A1 (en) 2020-12-24
US20180244763A1 (en) 2018-08-30
UY37575A (es) 2018-10-31
NZ756431A (en) 2025-03-28
CL2019002011A1 (es) 2019-11-22
IL323799A (en) 2025-12-01
JP7213186B2 (ja) 2023-01-26
JP2024038040A (ja) 2024-03-19
JP2023052376A (ja) 2023-04-11
TW202313678A (zh) 2023-04-01
AU2018209391A1 (en) 2019-09-05
CR20190375A (es) 2019-12-17
DOP2019000191A (es) 2019-10-15
CA3050845A1 (en) 2018-07-26
TWI856437B (zh) 2024-09-21
CO2019008946A2 (es) 2019-09-30
SG11201906660TA (en) 2019-08-27
CN110520441B (zh) 2023-11-14
AU2018209391B2 (en) 2024-08-15
CN110520441B8 (zh) 2024-07-09
TW201833135A (zh) 2018-09-16
MX2019008551A (es) 2020-01-27

Similar Documents

Publication Publication Date Title
TWI787230B (zh) 抗ＴＧＦ-β抗體及其用途
EP3494139B1 (en) Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
AU2015241037B2 (en) Anti-OX40 antibodies and methods of use
JP2021193096A (ja) Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
EP3571227A1 (en) Anti-tgf-beta antibodies and their use
CN108699154A (zh) 对btla具有特异性的抗体及其用途
CN107949571A (zh) 调控免疫反应的方法及抗体
JP2023502023A (ja) Ｃｄ２００受容体アンタゴニスト結合分子
KR102699080B1 (ko) 항-tgf-베타 항체 및 이의 용도
EA041300B1 (ru) Антитела к tgf-бета и их применение
EA049204B1 (ru) Антитела к tgf-бета и их применение
NZ796440A (en) Anti-TGF-beta antibodies and their use
HK1232891A1 (en) Anti-ox40 antibodies and methods of use
HK1232891B (en) Anti-ox40 antibodies and methods of use